A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

ClinicalTrials.gov ID: NCT00289016

Public ClinicalTrials.gov record NCT00289016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma

Study identification

NCT ID: NCT00289016
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: BioVex Limited; Industry
Enrollment: 50 participants

Conditions and interventions

Conditions

Melanoma

Interventions

Talimogene Laherparepvec Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2005
Primary completion: Nov 30, 2008
Completion: Apr 30, 2009
Last update posted: Dec 17, 2015

2005 – 2009

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
UCSD Cancer Center, Thornton Hospital	La Jolla	California	92093	—
UCLA	Los Angeles	California	90095	—
University of Colorado, Anschutz Cancer Pavillion	Aurora	Colorado	80010	—
Hubert H Humphrey Cancer Center	Robbinsdale	Minnesota	55422	—
Mountainside Hospital	Montclair	New Jersey	07042	—
Columbia University, Department of Surgery	New York	New York	10032	—
Mary Crowely Medical Research Center	Dallas	Texas	75246	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00289016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 17, 2015 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00289016 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →